Akkermansia Muciniphila Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 100 million AFU
Reference Brands: Pendulum Akkermansia (USA)
Category:
Nutraceuticals
Akkermansia muciniphila is available in Capsules
and strengths such as 100 million AFU.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Akkermansia muciniphila is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Akkermansia muciniphila can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Akkermansia muciniphila is a Gram-negative, anaerobic bacterium that naturally resides in the mucus layer of the intestinal lining in humans and animals. It plays an important role in maintaining gut health by degrading mucin, a key component of the intestinal mucus barrier. Through this activity, Akkermansia muciniphila helps maintain the integrity of the gut lining and supports a balanced gut microbiome, which is essential for overall digestive and metabolic health.
Scientific studies and metagenomic analyses have shown that lower levels of Akkermansia muciniphila in the gut are associated with several metabolic and inflammatory conditions, including inflammatory bowel disease (IBD), obesity, and type 2 diabetes. Because of this relationship, the bacterium has gained significant attention as a next-generation probiotic with potential immunomodulatory properties. Experimental studies have demonstrated that supplementation with Akkermansia muciniphila may help regulate immune responses, reduce inflammation, and support metabolic balance.
Preclinical research has also shown that this beneficial bacterium may slow the progression of metabolic disorders such as obesity and diabetes in animal models. As a result, clinical studies are currently being conducted to evaluate its effectiveness in humans. Due to its promising effects on gut barrier function, metabolism, and immune regulation, Akkermansia muciniphila is increasingly being explored as an advanced probiotic ingredient for supporting gut and metabolic health.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing